Method of treating multiple sclerosis
In one aspect, a method of treating a disorder associated with chronic inflammation includes administering to an individual in need thereof a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In some aspects, the disorder is a cancer, an autoimmune disorder, hypertension, or autism. In other aspects, isomyosmine is administered to treat viral infections or disorders associated with elevated levels of hydrogen peroxide and/or other Reactive Oxygen Species (ROS).
1. A method of treating multiple sclerosis comprising administering to an individual in need thereof a pharmaceutical composition containing a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the therapeutically effective amount is from about 0.001 to about 75 mg/kg/day.
3. The method of claim 1 , wherein the therapeutically effective amount is from about 0.01 to about 50 mg/kg/day.
4. The method of claim 1 , wherein the therapeutically effective amount is from about 0.1 to about 40 mg/kg/day.
5. The method of claim 1 , wherein the therapeutically effective amount is from about 1 to about 30 mg/kg/day.
6. The method of claim 1 , wherein the therapeutically effective amount is from about 1 to about 20 mg/kg/day.
7. The method of claim 1 , wherein the therapeutically effective amount is from about 1 to about 10 mg/kg/day.
8. The method of claim 1 , wherein the therapeutically effective amount is from about 1 to about 5 mg/kg/day.
9. The method of claim 1 , wherein the therapeutically effective amount is from about 5 to about 10 mg/kg/day.
10. The method of claim 1 , wherein the pharmaceutically acceptable salt is isomyosmine hydrochloride.
11. A method of inhibiting activation of Th1 cells in an individual suffering from multiple sclerosis comprising administering to the individual a pharmaceutical composition containing a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof.
12. The method of claim 11 , wherein the therapeutically effective amount is from about 0.001 to about 75 mg/kg/day.
13. The method of claim 11 , wherein the therapeutically effective amount is from about 0.01 to about 50 mg/kg/day.
14. The method of claim 11 , wherein the therapeutically effective amount is from about 0.1 to about 40 mg/kg/day.
15. The method of claim 11 , wherein the therapeutically effective amount is from about 1 to about 30 mg/kg/day.
16. The method of claim 11 , wherein the therapeutically effective amount is from about 1 to about 20 mg/kg/day.
17. The method of claim 11 , wherein the therapeutically effective amount is from about 1 to about 10 mg/kg/day.
18. The method of claim 11 , wherein the therapeutically effective amount is from about 1 to about 5 mg/kg/day.
19. The method of claim 11 , wherein the therapeutically effective amount is from about 5 to about 10 mg/kg/day.
20. The method of claim 11 , wherein the pharmaceutically acceptable salt is isomyosmine hydrochloride.